Compare EVAX & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVAX | BCG |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | Denmark | United States |
| Employees | N/A | 150 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 25.4M |
| IPO Year | 2020 | N/A |
| Metric | EVAX | BCG |
|---|---|---|
| Price | $3.12 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 21.3K | 15.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | ★ N/A | $56.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $1.36 |
| 52 Week High | $12.15 | $3.44 |
| Indicator | EVAX | BCG |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 48.89 |
| Support Level | $2.97 | $1.54 |
| Resistance Level | $3.61 | $1.68 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 32.79 | 62.50 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.